574 related articles for article (PubMed ID: 16110022)
1. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients.
Westra JL; Schaapveld M; Hollema H; de Boer JP; Kraak MM; de Jong D; ter Elst A; Mulder NH; Buys CH; Hofstra RM; Plukker JT
J Clin Oncol; 2005 Aug; 23(24):5635-43. PubMed ID: 16110022
[TBL] [Abstract][Full Text] [Related]
2. TP53 mutation and microsatellite instability status for the prediction of survival in adjuvant-treated colon cancer patients.
Watanabe T; Kanazawa T; Kazama Y; Tanaka J; Tanaka T; Ishihara S; Nagawa H
J Clin Oncol; 2005 Dec; 23(35):9031-2; author reply 9032-3. PubMed ID: 16339756
[No Abstract] [Full Text] [Related]
3. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
4. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
Kim GP; Colangelo LH; Wieand HS; Paik S; Kirsch IR; Wolmark N; Allegra CJ;
J Clin Oncol; 2007 Mar; 25(7):767-72. PubMed ID: 17228023
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
7. Combination of microsatellite instability and lymphocytic infiltrate as a prognostic indicator for adjuvant therapy in colon cancer.
Kumar S; Chang EY; Frankhouse J; Dorsey PB; Lee RG; Johnson N
Arch Surg; 2009 Sep; 144(9):835-40. PubMed ID: 19797108
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitivity and survival in gastric cancer patients with microsatellite instability.
Oki E; Kakeji Y; Zhao Y; Yoshida R; Ando K; Masuda T; Ohgaki K; Morita M; Maehara Y
Ann Surg Oncol; 2009 Sep; 16(9):2510-5. PubMed ID: 19565284
[TBL] [Abstract][Full Text] [Related]
9. Low microsatellite instability is associated with poor prognosis in stage C colon cancer.
Kohonen-Corish MR; Daniel JJ; Chan C; Lin BP; Kwun SY; Dent OF; Dhillon VS; Trent RJ; Chapuis PH; Bokey EL
J Clin Oncol; 2005 Apr; 23(10):2318-24. PubMed ID: 15800322
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
11. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
12. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
[TBL] [Abstract][Full Text] [Related]
13. Microsatellite instability did not predict individual survival in sporadic stage II and III rectal cancer patients.
Meng WJ; Sun XF; Tian C; Wang L; Yu YY; Zhou B; Gu J; Xia QJ; Li Y; Wang R; Zheng XL; Zhou ZG
Oncology; 2007; 72(1-2):82-8. PubMed ID: 18004081
[TBL] [Abstract][Full Text] [Related]
14. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Gill S; Loprinzi CL; Sargent DJ; Thomé SD; Alberts SR; Haller DG; Benedetti J; Francini G; Shepherd LE; Francois Seitz J; Labianca R; Chen W; Cha SS; Heldebrant MP; Goldberg RM
J Clin Oncol; 2004 May; 22(10):1797-806. PubMed ID: 15067028
[TBL] [Abstract][Full Text] [Related]
16. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A; Bazan V; Iacopetta B; Kerr D; Soussi T; Gebbia N;
J Clin Oncol; 2005 Oct; 23(30):7518-28. PubMed ID: 16172461
[TBL] [Abstract][Full Text] [Related]
17. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
[TBL] [Abstract][Full Text] [Related]
18. TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome.
Migliavacca M; Ottini L; Bazan V; Agnese V; Corsale S; Macaluso M; Lupi R; Dardanoni G; Valerio MR; Pantuso G; Di Fede G; Tomasino RM; Gebbia N; Mariani-Costantini R; Russo A
J Cell Physiol; 2004 Sep; 200(3):476-85. PubMed ID: 15254976
[TBL] [Abstract][Full Text] [Related]
19. A substantial proportion of microsatellite-unstable colon tumors carry TP53 mutations while not showing chromosomal instability.
Westra JL; Boven LG; van der Vlies P; Faber H; Sikkema B; Schaapveld M; Dijkhuizen T; Hollema H; Buys CH; Plukker JT; Kok K; Hofstra RM
Genes Chromosomes Cancer; 2005 Jun; 43(2):194-201. PubMed ID: 15729700
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of microsatellite instability in resectable pancreatic cancer.
Nakata B; Wang YQ; Yashiro M; Nishioka N; Tanaka H; Ohira M; Ishikawa T; Nishino H; Hirakawa K
Clin Cancer Res; 2002 Aug; 8(8):2536-40. PubMed ID: 12171881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
